Free Trial

Immix Biopharma (IMMX) Competitors

-0.22 (-8.73%)
(As of 05/21/2024 ET)


Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Eledon Pharmaceuticals (ELDN), Anebulo Pharmaceuticals (ANEB), Tiziana Life Sciences (TLSA), Kezar Life Sciences (KZR), CalciMedica (CALC), Kronos Bio (KRON), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.

Immix Biopharma vs.

Immix Biopharma (NASDAQ:IMMX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Eledon Pharmaceuticals' return on equity of -45.60% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -95.00% -78.89%
Eledon Pharmaceuticals N/A -45.60%-42.76%

Immix Biopharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$15.43M-$0.93-2.48
Eledon PharmaceuticalsN/AN/A-$40.33M-$1.38-2.23

Eledon Pharmaceuticals received 21 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 71.43% of users gave Eledon Pharmaceuticals an outperform vote.

Immix BiopharmaOutperform Votes
Underperform Votes
No Votes
Eledon PharmaceuticalsOutperform Votes
Underperform Votes

Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immix Biopharma presently has a consensus price target of $14.00, indicating a potential upside of 476.13%. Eledon Pharmaceuticals has a consensus price target of $11.67, indicating a potential upside of 282.51%. Given Immix Biopharma's higher possible upside, equities analysts plainly believe Immix Biopharma is more favorable than Eledon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, Immix Biopharma had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Immix Biopharma and 1 mentions for Eledon Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.40 beat Eledon Pharmaceuticals' score of -0.11 indicating that Immix Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Immix Biopharma Positive
Eledon Pharmaceuticals Neutral


Immix Biopharma and Eledon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMX vs. The Competition

MetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$61.01M$6.88B$5.03B$7.99B
Dividend YieldN/A2.73%44.98%3.91%
P/E Ratio-2.4811.33128.5015.30
Price / SalesN/A267.442,527.4477.99
Price / CashN/A20.5132.6829.27
Price / Book2.855.965.014.46
Net Income-$15.43M$143.44M$103.71M$213.05M
7 Day Performance5.00%0.95%0.88%0.91%
1 Month Performance5.48%5.36%5.51%6.20%
1 Year Performance40.85%-4.81%7.74%9.92%

Immix Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Eledon Pharmaceuticals
2.5512 of 5 stars
Anebulo Pharmaceuticals
2.7417 of 5 stars
+4.4%$58.44MN/A-5.432Positive News
Gap Up
High Trading Volume
Tiziana Life Sciences
0 of 5 stars
N/A-8.0%$57.55MN/A0.009Gap Up
Kezar Life Sciences
3.511 of 5 stars
2.8235 of 5 stars
+78.7%$59.61MN/A-0.2214Gap Down
Kronos Bio
3.666 of 5 stars
-45.0%$60.06M$6.29M-0.5062News Coverage
Checkpoint Therapeutics
3.8612 of 5 stars
-29.3%$55.67M$68,000.00-0.5623Analyst Revision
Gap Up
Carisma Therapeutics
1.5098 of 5 stars
Eagle Pharmaceuticals
3.4234 of 5 stars
-78.3%$60.66M$316.61M3.96134Analyst Forecast
News Coverage
AEON Biopharma
0 of 5 stars
N/A$61.60MN/A0.0010Analyst Revision
Gap Down

Related Companies and Tools

This page (NASDAQ:IMMX) was last updated on 5/21/2024 by Staff

From Our Partners